Monitoring and deciphering protein degradation pathways inside cells

泛素连接酶 泛素 药物发现 三元络合物 蛋白质降解 蛋白质水解 小分子 DNA连接酶 化学 细胞生物学 降级(电信) 连接器 药物开发 靶蛋白 生物 生物化学 计算生物学 蛋白酶体 药品 药理学 计算机科学 操作系统 基因 电信
作者
Danette L. Daniels,Kristin M. Riching,Marjeta Urh
出处
期刊:Drug Discovery Today: Technologies [Elsevier BV]
卷期号:31: 61-68 被引量:45
标识
DOI:10.1016/j.ddtec.2018.12.001
摘要

A new series of therapeutic modalities resulting in degradation of target proteins, termed proteolysis targeting chimeras (PROTACs), hold significant therapeutic potential with possible prolonged pharmacodynamics, improved potency, and ability to target proteins previously thought of as “undruggable”. PROTACs are heterobifunctional small molecules consisting of a target binding handle bridged via a chemical linker to an E3 ligase handle which recruit the E3 ligase and ubiquitin machinery to target proteins, resulting in subsequent ubiquitination and degradation of the target. With the generation of small molecule PROTAC compound libraries for drug discovery, it becomes essential to have sensitive screening technologies to rapidly profile activity and have assays which can clearly inform on performance at the various cellular steps required for PROTAC-mediated degradation. For PROTAC compounds, this has been particularly challenging using either biochemical or cellular assay approaches. Biochemical assays are highly informative for the first part of the degradation process, including optimization of compound binding to targets and interrogation of target:PROTAC:E3 ligase ternary complex formation, but struggle with the remaining steps; recruitment of ternary complex into larger active E3 ligase complexes, ubiquitination, and proteasomal degradation. On the other hand, cellular assays are excellent at determining if the PROTAC successfully degrades the target in its relevant setting but struggle as early development PROTAC compounds are often poorly cell-permeable given their high molecular weight. Additionally, if degradation is not observed in a cellular assay, it is difficult to deconvolute the reason why or at which step there was failure. In this review we will highlight the current approaches along with recent advances to overcome the challenges faced for cellular PROTAC screening, which will enable and advance drug discovery of therapeutic degradation compounds.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
木木木发布了新的文献求助10
刚刚
Theprisoners发布了新的文献求助10
1秒前
1秒前
爱打麻将的小狗完成签到,获得积分10
2秒前
2秒前
3秒前
4秒前
lin发布了新的文献求助10
4秒前
颜九伊发布了新的文献求助10
5秒前
朴实香露发布了新的文献求助10
5秒前
传奇3应助wangtian采纳,获得10
5秒前
5秒前
搜集达人应助1111采纳,获得10
5秒前
王饱饱发布了新的文献求助10
5秒前
5秒前
深情安青应助DCC采纳,获得10
6秒前
maox1aoxin应助畅快海云采纳,获得50
6秒前
以利沙发布了新的文献求助10
6秒前
6秒前
7秒前
Adrian完成签到,获得积分20
7秒前
Yanran完成签到,获得积分20
7秒前
dawnstar应助文件撤销了驳回
7秒前
7秒前
8秒前
湘25alety完成签到,获得积分20
8秒前
8秒前
9秒前
9秒前
9秒前
奥特曼打小怪兽完成签到,获得积分10
9秒前
9秒前
9秒前
9秒前
yyy发布了新的文献求助10
10秒前
10秒前
10秒前
LIULU完成签到,获得积分10
10秒前
glucose发布了新的文献求助10
10秒前
橙色发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Digital Twins of Advanced Materials Processing 2000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6040539
求助须知:如何正确求助?哪些是违规求助? 7776530
关于积分的说明 16231049
捐赠科研通 5186584
什么是DOI,文献DOI怎么找? 2775455
邀请新用户注册赠送积分活动 1758546
关于科研通互助平台的介绍 1642192